Common Contracts
3 similar Product License and Collaboration Agreement contracts by BG Medicine, Inc.
PRODUCT LICENSE AND COLLABORATION AGREEMENTProduct License and Collaboration Agreement • February 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories
This Product License and Collaboration Agreement (this “Agreement”) is made and entered into as of this 4 day of May, 2007 (the “Effective Date”), by and between (i) BG Medicine, Inc., a Delaware corporation (“BGM”), (ii) ACS Biomarker B.V. i.o. (“ACSB”), a corporation to be established by the University of Maastricht (the “University”), BioMedbooster B.V., a corporation organized under the laws of The Netherlands (“BioMedbooster”), Yigal Pinto, Mat Daemen, Tilman Hackeng and Marcel Kannekens, and (iii) solely for purposes of Section 3.04 hereof, the University and BioMedbooster.
PRODUCT LICENSE AND COLLABORATION AGREEMENTProduct License and Collaboration Agreement • December 4th, 2007 • BG Medicine, Inc. • Services-medical laboratories
This Product License and Collaboration Agreement (this “Agreement”) is made and entered into as of this 4 day of May, 2007 (the “Effective Date”), by and between (i) BG Medicine, Inc., a Delaware corporation (“BGM”), (ii) ACS Biomarker B.V. i.o. (“ACSB”), a corporation to be established by the University of Maastricht (the “University”), BioMedbooster B.V., a corporation organized under the laws of The Netherlands (“BioMedbooster”), Yigal Pinto, Mat Daemen, Tilman Hackeng and Marcel Kannekens, and (iii) solely for purposes of Section 3.04 hereof, the University and BioMedbooster.
PRODUCT LICENSE AND COLLABORATION AGREEMENTProduct License and Collaboration Agreement • August 24th, 2007 • BG Medicine, Inc. • Services-medical laboratories
This Product License and Collaboration Agreement (this “Agreement”) is made and entered into as of this 4 day of May, 2007 (the “Effective Date”), by and between (i) BG Medicine, Inc., a Delaware corporation (“BGM”), (ii) ACS Biomarker B.V. i.o. (“ACSB”), a corporation to be established by the University of Maastricht (the “University”), BioMedbooster B.V., a corporation organized under the laws of The Netherlands (“BioMedbooster”), Yigal Pinto, Mat Daemen, Tilman Hackeng and Marcel Kannekens, and (iii) solely for purposes of Section 3.04 hereof, the University and BioMedbooster.
